Gene therapy comes of age: We can now edit entire genomes to cure diseases

For a long time, people thought HIV was incurable. The main reason was that HIV is a retrovirus, meaning that it inserts its own viral DNA into the genome of its host perhaps we could treat the symptoms of HIV, but many doubted it was possible to actually correct the genes themselves.Our techniques for slicing up DNA are very advanced when that DNA sits suspended in a test solution, but nearly useless when we need to accurately edit millions of copies of a gene spread throughout a complex, living animal. Technologies aimed at addressing that problem have been the topic of intense study in recent years, and this week MIT announced that one of the most promising lines of research has achieved its first major goal: researchers have permanently cured a genetic disease in an adult animal.

This is a proof of concept for something medicine has been teasing for decades: useful, whole-body genome editing in fully developed adults. Until recently, most such manipulation was possible only during early development and many genetic diseases dont make themselves known until after birth, or even much later in life. While breakthroughs in whole-genome sequencing are bringing genetic early-warning to awhole new level for parents, there are still plenty of ways to acquire problem DNA later in life most notably, through viruses like HIV. Whether were talking about a hereditary genetic disease like Alzheimers or an acquired one like radiation damage, MITs newest breakthrough has the potential to help.

A simplified schematic of the CRISPR system. RNA guides Cas9 in cutting at the CRISPR sequences.

In this study[doi:10.1038/nbt.2884], researchers attacked a disease called hereditarytyrosinemia, which stops liver cells from being able to process the amino acid tyrosine. It is caused by a mutation in just a single base of a single gene on the mouse (and human) genome, and prior research has confirmed that fixing that mutation cures the disease. The problem is that, until now, such a correction was only possible during early development, or even before fertilization of the egg. An adult body was thought to be simply too complex a target.

The gene editing technology used here is called the CRISPR system, which refers to the Clustered Regularly Interspaced Short Palindromic Repeats that allow its action.As the name suggests, the system inserts short palindromic DNA sequences called CRISPRs that are a defining characteristic of viral DNA. Bacteria have an evolved defense that finds these CRISPRs, treating them (correctly, until now) as evidence of unwanted viral DNA. Scientists insert DNA sequences that code for this bacterial cutting enzyme, along with the healthy version of our gene of interest and some extra RNA for targeting. All scientists need do is design their sequences so CRISPRs are inserted into the genome around the diseased gene, tricking the cell into identifying it as viral from there, the cell handles the excision all on its own, replacing the newly viral gene with the studys healthy version. The whole process plays out using the cells own machinery.

This is how MIT chose to visualize the process.

The experimental material actually enters the body via injection, targeted to a specific cell type.In this study, researchers observed an initial infection rate of roughly 1 in every 250 target cells. Those healthy cells out-competed their unmodified brothers, and within a month the corrected cells made up more than a third of the target cell type. This effectively cured the disease; when the mice were taken off of previously life-saving medication, they survived with little ill effect.

There are other possible solutions to the problem of adult gene editing, but they can be much more difficult to use,less accurate and reliable, and are generally useful in a narrower array of circumstances. CRISPRs offer a very high level of fidelity in targeting, both to specific cells in the body and to very specific genetic loci within each cell.

Tyrosinemia affects only about 1 in every 100,000 people, but the science on display here is very generalizable. While many diseases will require a more nuanced approach than was used here, many will not; wholly replacing genes in adult animals is a powerful tool, capable of curing many, many diseases. Not every cell type will lend itself as well to the CRISPR system, nor every disease; particularly, this study relies on the fact that corrected cells will naturally replace disease cells, improving their initial infection rate. That wont always be possible, unfortunately.

Theres also very little standing between this technique and non-medical applications can you drug test an athlete or academic for the contents of their own genome? These questions and more will become relevant over the next few decades, though their effects should be minuscule when weighed against the positive impacts of the medical applications.

Read more from the original source:

Gene therapy comes of age: We can now edit entire genomes to cure diseases

Defending a Convicted Husband, Evidence Tampering and Sheriff’s Misconduct with Kathy Anderson – Video


Defending a Convicted Husband, Evidence Tampering and Sheriff #39;s Misconduct with Kathy Anderson
Dr. W. French Anderson, a pioneer of gene therapy, was convicted of sexual abuse against a minor and is now serving a 14 year jail sentence for his crimes. W...

By: TheLipTV

More:

Defending a Convicted Husband, Evidence Tampering and Sheriff's Misconduct with Kathy Anderson - Video

Biotech company Spark Therapeutics, Irish firm to partner on blindness drug

Spark Therapeutics L.L.C., a Philadelphia company developing gene-based medicines for debilitating diseases, has signed a collaborative partnership with a gene-therapy firm in Ireland to develop a product to treat a rare form of blindness, the companies announced Tuesday.

Spark, a biotechnology company spun out of research at Children's Hospital of Philadelphia, said Dublin-based Genable Technologies Ltd. will license certain patents from Spark, which will be the exclusive manufacturer and provide development expertise for a potential treatment for blindness caused by inherited retinal dystrophy.

Spark will receive milestone payments and royalties on future sales, as well as revenue from the manufacturing and supply of the product. Financial terms were not disclosed.

Children's Hospital has committed to investing up to $50 million in Spark, which seeks to be the nation's first commercial provider of gene therapy.

Genable's therapeutic strategy "knocks down" or suppresses the "over-expression of one gene" causing a disease, while at the same time "replacing something else that is missing in the patient," Marrazzo said in an interview.

Spark is developing two potential products to treat inherited retinal disease. One is in a late-stage, or Phase 3, clinical trial, "which is likely to be the first approved gene therapy in the United States," Marrazzo said.

A second drug candidate for retinal disease will begin clinical trials shortly. "We haven't announced the specifics of that program yet," he said.

Initial results on its lead drug candidate in late-stage testing have been promising, Spark said: Once-blind patients could recognize faces and were moved out of Braille classrooms. They were no longer considered legally blind, and some were able to drive a car.

Excerpt from:

Biotech company Spark Therapeutics, Irish firm to partner on blindness drug

Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy

Retinitis pigmentosa is the most common inherited eye disease. Mutations in the gene for rhodopsin, the pigment for photoreceptor cells in the retina responsible for the perception of light, account for 15 percent of retinitis pigmentosa cases. CHOP spinout Spark Therapeutics, which has a late stage retinitis pigmentosa gene therapy treatment under development, is collaborating with Ireland-based biopharma company Genable Technologies, according to a company statement.

The deal will focus on Genables lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa, called GT038. Under the deal terms, Genable will license certain manufacturing patents from Spark. Philadelphia-based Spark will be the exclusive manufacturer of the product and provide development advice and expertise to Genable to help in its development of GT038. In exchange, Spark received an initial payment and will receive subsequent milestone payments and royalties on future sales of GT038, and near-term revenue from the manufacture and supply of the product, according to the statement.

In response to emailed questions a spokeswoman for Spark Therapeutics said: Generally, the company recognizes that there are a significant number of severe genetic diseases without effective treatments in therapeutic areas where it has significant expertise (for example, inherited blindness, hematologic disorders, neurodegenerative diseases), and if Spark can play a role in expanding the number of products that get to market through partnerships, the team will certainly entertain those possibilities.

Rhodopsin-linked autosomal dominant retinitis pigmentosa affects roughly 30,000 people worldwide and there are currently no drugs to treat it. Genables retinitis pigmentosa gene therapy is designed to suppresses the expression of faulty and normal copies of the rhodopsin gene and restores normal gene expression.

Its treatment has been given Orphan Drug Designation in both the U.S. and Europe which extends the exclusivity for the treatment, if its approved, and gives the company certain tax credits. Genable has the rights to market its treatment globally, if it succeeds in getting the treatment approved.

Spark Therapeutics has a few gene therapies under development. One is for patients with inherited Lebers congenital amaurosis and retinitis pigmentosa. Another is for Hemophilia B in Phase 1/2 development. Earlier this year CEO Jeff Marrazzo said the company expects to have data from a Phase 3 open-label, randomized control trial for its treatment for blindness caused by mutations of the RPE65 gene available in the first half of next year.

Get our daily newsletter or follow us.

Please enter your email below:

Read the original post:

Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy

From mouse ears to human's? Gene therapy to address progressive hearing loss

One in a thousand children in the United States is deaf, and one in three adults will experience significant hearing loss after the age of 65. Whether the result of genetic or environmental factors, hearing loss costs billions of dollars in healthcare expenses every year, making the search for a cure critical.

Now a team of researchers led by Karen B. Avraham of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University's Sackler Faculty of Medicine and Yehoash Raphael of the Department of Otolaryngology-Head and Neck Surgery at University of Michigan's Kresge Hearing Research Institute have discovered that using DNA as a drug -- commonly called gene therapy -- in laboratory mice may protect the inner ear nerve cells of humans suffering from certain types of progressive hearing loss.

In the study, doctoral student Shaked Shivatzki created a mouse population possessing the gene that produces the most prevalent form of hearing loss in humans: the mutated connexin 26 gene. Some 30 percent of American children born deaf have this form of the gene. Because of its prevalence and the inexpensive tests available to identify it, there is a great desire to find a cure or therapy to treat it.

"Regenerating" neurons

Prof. Avraham's team set out to prove that gene therapy could be used to preserve the inner ear nerve cells of the mice. Mice with the mutated connexin 26 gene exhibit deterioration of the nerve cells that send a sound signal to the brain. The researchers found that a protein growth factor used to protect and maintain neurons, otherwise known as brain-derived neurotrophic factor (BDNF), could be used to block this degeneration. They then engineered a virus that could be tolerated by the body without causing disease, and inserted the growth factor into the virus. Finally, they surgically injected the virus into the ears of the mice. This factor was able to "rescue" the neurons in the inner ear by blocking their degeneration.

"A wide spectrum of people are affected by hearing loss, and the way each person deals with it is highly variable," said Prof. Avraham. "That said, there is an almost unanimous interest in finding the genes responsible for hearing loss. We tried to figure out why the mouse was losing cells that enable it to hear. Why did it lose its hearing? The collaborative work allowed us to provide gene therapy to reverse the loss of nerve cells in the ears of these deaf mice."

Although this approach is short of improving hearing in these mice, it has important implications for the enhancement of sound perception with a cochlear implant, used by many people whose connexin 26 mutation has led to impaired hearing.

Embryonic hearing?

Inner ear nerve cells facilitate the optimal functioning of cochlear implants. Prof. Avraham's research suggests a possible new strategy for improving implant function, particularly in people whose hearing loss gets progressively worse with time, such as those with profound hearing loss as well as those with the connexin gene mutation. Combining gene therapy with the implant could help to protect vital nerve cells, thus preserving and improving the performance of the implant.

More research remains. "Safety is the main question. And what about timing? Although over 80 percent of human and mouse genes are similar, which makes mice the perfect lab model for human hearing, there's still a big difference. Humans start hearing as embryos, but mice don't start to hear until two weeks after birth. So we wondered, do we need to start the corrective process in utero, in infants, or later in life?" said Prof. Avraham.

The rest is here:

From mouse ears to human's? Gene therapy to address progressive hearing loss

Gene implicated in progression and relapse of deadly breast cancer finding points to potential Achilles' heel in …

PUBLIC RELEASE DATE:

24-Mar-2014

Contact: Jen Gundersen jeg2034@med.cornell.edu 646-317-7402 Weill Cornell Medical College

NEW YORK (March 24, 2014) Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses. Patients typically relapse within one to three years of being treated.

Senior author Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, wanted to know whether the gene already understood from her prior work to be a critical regulator of immune and metabolic functions was important to cancer's ability to adapt and thrive in the oxygen- and nutrient-deprived environments inside of tumors. Using cells taken from patients' tumors and transplanted into mice, Dr. Glimcher's team found that the gene, XBP1, is especially active in triple negative breast cancer, particularly in the progression of malignant cells and their resurgence after treatment.

"Patients with the triple negative form of breast cancer are those who most desperately need new approaches to treat their disease," said Dr. Glimcher, who is also a professor of medicine at Weill Cornell. "This pathway was activated in about two-thirds of patients with this type of breast cancer. Now that we better understand how this gene helps tumors proliferate and then return after a patient's initial treatment, we believe we can develop more effective therapies to shrink their growth and delay relapse."

The group, which included investigators from nine institutions, examined several types of breast cancer cell lines. They found that XBP1 was particularly active in basal-like breast cancer cells cultivated in the lab and in triple negative breast cancer cells from patients. When they suppressed the activity of the gene in laboratory cell cultures and animal models, however, the researchers were able to dramatically reduce the size of tumors and the likelihood of relapse, especially when these approaches were used in conjunction with the chemotherapy drugs doxorubicin or paclitexel. The finding suggests that XBP1 controls behaviors associated with tumor-initiating cells that have been implicated as the originators of tumors in a number of cancers, including that of the breast, supporting the hypothesis that combination therapy could be an effective treatment for triple negative breast cancer.

The scientists also found that interactions between XBP1 and another transcriptional regulator, HIF1-alpha, spurs the cancer-driving proteins. Silencing XBP1 in the TNBC cell lines reduced the tumor cells' growth and other behaviors typical of metastasis.

"This starts to demonstrate how cancer cells co-opt the endoplasmic reticulum stress response pathway to allow tumors to grow and survive when they are deprived of nutrients and oxygen," said lead author Dr. Xi Chen, a postdoctoral associate at Weill Cornell, referring to the process by which healthy cells maintain their function. "It shows the interaction between two critical pathways to make the cells better able to deal with a hostile microenvironment, and in that way offers new strategies to target triple negative breast cancer."

More:

Gene implicated in progression and relapse of deadly breast cancer finding points to potential Achilles' heel in ...

From mouse ears to man's?

PUBLIC RELEASE DATE:

24-Mar-2014

Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University

One in a thousand children in the United States is deaf, and one in three adults will experience significant hearing loss after the age of 65. Whether the result of genetic or environmental factors, hearing loss costs billions of dollars in healthcare expenses every year, making the search for a cure critical.

Now a team of researchers led by Karen B. Avraham of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University's Sackler Faculty of Medicine and Yehoash Raphael of the Department of OtolaryngologyHead and Neck Surgery at University of Michigan's Kresge Hearing Research Institute have discovered that using DNA as a drug commonly called gene therapy in laboratory mice may protect the inner ear nerve cells of humans suffering from certain types of progressive hearing loss.

In the study recently published in the journal Hearing Research, doctoral student Shaked Shivatzki created a mouse population possessing the gene that produces the most prevalent form of hearing loss in humans: the mutated connexin 26 gene. Some 30 percent of American children born deaf have this form of the gene. Because of its prevalence and the inexpensive tests available to identify it, there is a great desire to find a cure or therapy to treat it.

"Regenerating" neurons

Prof. Avraham's team set out to prove that gene therapy could be used to preserve the inner ear nerve cells of the mice. Mice with the mutated connexin 26 gene exhibit deterioration of the nerve cells that send a sound signal to the brain. The researchers found that a protein growth factor used to protect and maintain neurons, otherwise known as brain-derived neurotrophic factor (BDNF), could be used to block this degeneration. They then engineered a virus that could be tolerated by the body without causing disease, and inserted the growth factor into the virus. Finally, they surgically injected the virus into the ears of the mice. This factor was able to "rescue" the neurons in the inner ear by blocking their degeneration.

"A wide spectrum of people are affected by hearing loss, and the way each person deals with it is highly variable," said Prof. Avraham. "That said, there is an almost unanimous interest in finding the genes responsible for hearing loss. We tried to figure out why the mouse was losing cells that enable it to hear. Why did it lose its hearing? The collaborative work allowed us to provide gene therapy to reverse the loss of nerve cells in the ears of these deaf mice."

Although this approach is short of improving hearing in these mice, it has important implications for the enhancement of sound perception with a cochlear implant, used by many people whose connexin 26 mutation has led to impaired hearing.

See the article here:

From mouse ears to man's?

Gene therapy to help with epileptic seizures

It is brain awareness week and University of Auckland researchers say they have developed a promising treatment for the 30 percent of epileptics who do not respond to drugs.

Researchers say it cuts the length of seizures in half and they hope to soon be able to tell whether it reduces the frequency of them too.

Epileptic Bevan McClay has been prescribed a cocktail of pills to help him manage, but the camera shop sales consultant just can't find the right combination to keep his epileptic seizures at bay.

"It gets a little bit frustrating sometimes," says Mr McClay.

Seizures affect one in every 100 people in New Zealand. That's 40,000 people. One-third of sufferers do not respond to conventional treatment.

But University of Auckland researches say they have discovered how to turn the gene off in the brain that is responsible for causing seizures.

"It could have a significant effect on any potential future treatment for epilepsy," says researcher Debbie Young.

How they do it is quite ingenious. They place a piece of synthetic DNA called a gene silencer inside a tiny capsule. That is injected and attaches to the cell containing the overactive gene. As the capsule breaks down, it releases the silencer, which switches off the overactive gene. That in turn releases increased levels of a chemical involved in stopping the seizures.

Researchers say the treatment can halve the length of seizures, and they are now looking at whether it can reduce the frequency of them too. That is giving hope to sufferers and those treating the disease.

"My clinics are full of people whom I feel I can help very little," says Dr Peter Bergin, a neurologist at Auckland Hospital and medical director for the Epilepsy Research programme. "It's enormously frustrating for me and I feel greatly for the patients."

Here is the original post:

Gene therapy to help with epileptic seizures